How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7,238 results for

Diarrhea Secondary to Medications

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Managing Medication-induced Constipation in Cancer: A Clinical Trial

an eight week period and to evaluate the relationship between constipation intensity and vinca alkaloid dose. Secondary Outcome Measures : Phase II - Number of Participants With Desired Effect - Patients with Medication-induced Constipation [ Time Frame: 2 years, 3 months ] To test the efficacy of a Constipation Treatment Protocol in patients with medication-induced constipation. Phase II - Best Determination of Laxative Dose - Patients with Medication-induced Constipation [ Time Frame: 2 years, 3 (...) Managing Medication-induced Constipation in Cancer: A Clinical Trial Managing Medication-induced Constipation in Cancer: A Clinical Trial - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Managing Medication

2011 Clinical Trials

182. A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.

A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus. A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study (...) Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus. (ADHERE) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated

2011 Clinical Trials

183. Secondary Erythrocytosis

Secondary Erythrocytosis Secondary Erythrocytosis - Hematology and Oncology - MSD Manual Professional Edition Brought to you by The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases / / / / IN THIS TOPIC OTHER TOPICS IN THIS CHAPTER Test your knowledge Multiple (...) of ADP Receptor ADP receptors are integral proteins embedded in a platelet membrane. When ADP binds, it causes a conformational change in the fibrinogen receptor, which allows fibrinogen to bind to the receptors... SOCIAL MEDIA Add to Any Platform Loading , MD, James P. Wilmot Cancer Institute, University of Rochester Medical Center; , MD, University of Rochester Medical Center Click here for Patient Education NOTE: This is the Professional Version. CONSUMERS: Secondary erythrocytosis

2013 Merck Manual (19th Edition)

184. Secondary Adrenal Insufficiency

Secondary Adrenal Insufficiency Secondary Adrenal Insufficiency - Endocrine and Metabolic Disorders - MSD Manual Professional Edition Brought to you by The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases / / / / IN THIS TOPIC OTHER TOPICS IN THIS CHAPTER Test (...) Endocrine System Video Overview of Buffering and the Henderson-Hasselbalch Equation SOCIAL MEDIA Add to Any Platform Loading , MD, University of Oxford; Fellow, Green-Templeton College Click here for Patient Education NOTE: This is the Professional Version. CONSUMERS: Topic Resources Secondary adrenal insufficiency is adrenal hypofunction due to a lack of adrenocorticotropic hormone (ACTH). Symptoms are the same as for and include fatigue, weakness, weight loss, nausea, vomiting, and diarrhea

2013 Merck Manual (19th Edition)

185. Secondary Iron Overload

Secondary Iron Overload Secondary Iron Overload - Hematology and Oncology - MSD Manual Professional Edition Brought to you by The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases / / / / IN THIS TOPIC OTHER TOPICS IN THIS CHAPTER Test your knowledge Multiple (...) Biopsy SOCIAL MEDIA Add to Any Platform Loading , MD, Johns Hopkins University School of Medicine Click here for Patient Education NOTE: This is the Professional Version. CONSUMERS: Secondary iron overload results from excess absorption of iron, repeated blood transfusions, or excess oral intake, typically in patients with disorders of erythropoiesis. Consequences can include systemic symptoms, liver disorders, cardiomyopathy, diabetes, erectile dysfunction, and arthropathy. Diagnosis is by elevated

2013 Merck Manual (19th Edition)

186. Lactobacillus Reuteri in the Prevention of Antibiotic Associated-diarrhea and Clostridium Difficile

Sponsor: Case Western Reserve University Collaborator: BioGaia AB Information provided by (Responsible Party): Alison Steiber, Case Western Reserve University Study Details Study Description Go to Brief Summary: The purpose of this study is to find whether Lactobacillus reuteri prevents antibiotic-associated diarrhea and related Clostridium difficile infections. Subjects will be admitted from the University Hospitals Case Medical Center. They will be randomly assigned to an intervention group (...) receiving L. reuteri or a placebo. Supplementation will occur during antibiotic treatment and for an additional 7 days after cessation of treatment. Data collection will occur at baseline, end of antibiotic use, 7 days after antibiotic cessation, and 21 days after antibiotic cessation. Primary data includes diarrhea instances. Secondary data includes severity of diarrhea, presence of C. difficile toxins, and presence of other GI symptoms. Condition or disease Intervention/treatment Phase Antibiotic

2010 Clinical Trials

187. Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia

Posted : December 31, 2010 Last Update Posted : July 21, 2011 Sponsor: Sprim Advanced Life Sciences Information provided by: Sprim Advanced Life Sciences Study Details Study Description Go to Brief Summary: Primary Objective: • To confirm the efficacy of the probiotic product Healthy Trinity (retail label)/Trenev Trio (professional label) in the improvement of symptoms in adult patients with diarrhea-predominant irritable bowel syndrome (IBS-D) and functional dyspepsia Secondary Objective (...) Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum

2010 Clinical Trials

188. LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

adequately to other IBS therapy will be eligible to enroll in the study. Criteria Inclusion Criteria: Be a female between 18 and 65 years of age (inclusive) at Visit 1. Sign and date a written informed consent form prior to the initiation of any study-related activities, including discontinuation of any prohibited medications. Be diagnosed with severe, diarrhea-predominant IBS. Have experienced chronic IBS symptoms lasting 6 months or longer. Have not responded adequately to other IBS therapy. Be able (...) LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. LOTRONEX®

2010 Clinical Trials

189. Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D) With LACTEOL® 340 mg

Posted : March 21, 2017 Sponsor: Forest Laboratories Information provided by (Responsible Party): Forest Laboratories Study Details Study Description Go to Brief Summary: Irritable bowel syndrome is a complex condition with a high unmet medical need for effective and safe treatment options. Lacteol® is a lactobacillus product used for adjunctive and symptomatic treatment of diarrhea. In this study, Lacteol® 340 mg will be evaluated as a potential therapy for the treatment of diarrhea-predominant (...) irritable bowel syndrome (IBS-D). Condition or disease Intervention/treatment Phase Diarrhea-predominant Irritable Bowel Syndrome Drug: LACTEOL® 340 mg Drug: PLACEBO Phase 3 Detailed Description: This study will include the following phases: Screening Phase, Run-In Phase, Double-Blind Treatment Phase and Open-Label Treatment Phase. Screening: Eligibility of subjects will be evaluated following informed consent signature. Screening procedures/evaluations (physical exam, concomitant medications, clinical

2010 Clinical Trials

190. Zinc Supplementation to Reduce Diarrhea Rates in Adults in Western Kenya.

is defined as 3 or more loose motions within a period of 24 hours. Field workers will visit each subject to record diarrhea morbidity data, daily for 104 days. Secondary Outcome Measures : Determine the time to diarrhea onset in both groups [ Time Frame: Daily, for 104 days ] Daily, field workers will visit each subject to dispense supplement and to record diarrhea morbidity data. The time between day 0 and the first bout of diarrhea will be noted. Determine the duration of each diarrhea episode in both (...) . Effect of Zinc Supplementation on Diarrhea and Malaria Morbidity in Adults in Rural Kenya. FASEB J. 2010 24:538.12 AG Scrimgeour, HC Lukaski, ME Polhemus, L Otieno, AJ Young, ME Bovill. Zinc supplementation does not alter plasma trace elements in Kenyan adults FASEB J. 2009 23:922.2. Other Publications: Layout table for additonal information Responsible Party: LTC Maria Bovill, US Army Medical Research Unit - Kenya ClinicalTrials.gov Identifier: Other Study ID Numbers: USARIEM C07-04 WRAIR 1332

2010 Clinical Trials

191. Safety, Efficacy and Cost-effectiveness of Racecadotril in Children With Acute Diarrhea in Mexico

and then classified as related or non related and as severe or notr severe adverse event Secondary Outcome Measures : The pharmacoeconomics analysis [ Time Frame: 2007-2009 ] The pharmacoeconomics model consisted in a theoretical scheme that makes it possible to conduct simulations of health processes associated with medical care, use of medications, expenses for intravenous hydration and re-hospitalizations secondary to dehydration, through estimates obtained from the efficacy data available from our clinical (...) Safety, Efficacy and Cost-effectiveness of Racecadotril in Children With Acute Diarrhea in Mexico Safety, Efficacy and Cost-effectiveness of Racecadotril in Children With Acute Diarrhea in Mexico - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2010 Clinical Trials

192. Efficacy of Zinc Sulfate With Probiotics for the Treatment of Acute Diarrhea in Children

endpoint of our study is the time of acute diarrhea Secondary Outcome Measures : number of stools in consequent days [ Time Frame: 15 days ] The secondary end points will be number of stools per day, necessity of hospitalization or not, tolerability and adherence to the therapy Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join (...) Efficacy of Zinc Sulfate With Probiotics for the Treatment of Acute Diarrhea in Children Efficacy of Zinc Sulfate With Probiotics for the Treatment of Acute Diarrhea in Children - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies

2010 Clinical Trials

193. Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)

of and willing to give informed consent Exclusion Criteria Patients were excluded from the study if they met any of the following criteria: Fever (> 100.4F or 38C) or presence of signs and symptoms of systemic infection Note: antipyretic medication should not have been administered in the 6 hours before this assessment Known or suspected infection with non-bacterial pathogen before randomization Presence of diarrhea for > 72 hours duration Presence of grossly bloody stool Presence of moderate to severe (...) Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD) Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached

2010 Clinical Trials

194. Sulfasalazine in Preventing Acute Diarrhea in Patients With Cancer Who Are Undergoing Pelvic Radiation Therapy

(CTCAE), Version 4.0. Grade 0 = None; 1=Mild; Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening as measured by the CTCAE version 4.0. Assessments were recorded during the course of RT and for 6 weeks following RT. The table below represents the worst graded diarrhea for each patient. A two-sided Wilcoxon rank-sum test will be used to test the equality of the distributions of maximum diarrhea severity grades between the two treatment arms. Secondary Outcome Measures : Maximum Severity of Each (...) Outcome Variable (Rectal Bleeding, Abdominal Cramping, Tenesmus, Constipation, and Diarrhea) Measured During and After RT [ Time Frame: During radiation therapy and up to 6 weeks post radiation therapy ] The maximal severity of each of 5 different adverse even types (Tenesmus, Abdominal Pain, Constipation, Diarrhea, and Rectal Bleeding) were collected as a secondary endpoint. Severity of the events was graded using the terminology and grading categories defined in the NCI's Common Toxicity Criteria

2010 Clinical Trials

195. Oral Zinc for the Treatment of Acute Diarrhea in US Children

of zinc supplementation in all children with diarrhea despite little or no data from trials in industrialized/developed settings. In the United States over 4 million children suffer annually from diarrheal illness. Although mortality is not a significant factor in U.S. cases, 75% of all cases present to medical care resulting in over 200,000 hospitalizations annually for diarrhea. This has significant impact on U.S. healthcare costs, with an average of $391 per outpatient treatment and $2,549 per (...) have included Oral Rehydration Solution (ORS), introduced 30 years ago by the WHO, which continues to provide a safe and effective way to maintain hydration during acute illness. ORS, however, does not reduce the volume or frequency of stool output in diarrhea. The anti-diarrheal medication loperamide (Imodium®) was commonly used in children until reports of serious adverse reactions caused its use to fall out of favor. There are no other medications or supplements available to specifically treat

2010 Clinical Trials

196. Probiotics for Infectious Diarrhea in Children in South India

: Clinical Trials Registry of India ) First Posted: May 26, 2010 Last Update Posted: February 4, 2015 Last Verified: February 2015 Keywords provided by Gagandeep Kang, Christian Medical College, Vellore, India: rotavirus cryptosporidium probiotics intestinal function immune response Additional relevant MeSH terms: Layout table for MeSH terms Diarrhea Communicable Diseases Infection Gastroenteritis Dysentery Signs and Symptoms, Digestive Signs and Symptoms Gastrointestinal Diseases Digestive System (...) Probiotics for Infectious Diarrhea in Children in South India Probiotics for Infectious Diarrhea in Children in South India - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Probiotics for Infectious Diarrhea

2010 Clinical Trials

197. Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS) Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01100684 Recruitment Status : Completed First Posted : April 9, 2010 Last Update Posted : December 18, 2013 Sponsor: Tioga Pharmaceuticals Collaborator: RTI

2010 Clinical Trials

198. Confocal Laser Endomicroscopy (CLE) in Patients With Diarrhea

) in Patients With Diarrhea The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01072110 Recruitment Status : Unknown Verified January 2013 by Helmut Neumann, University of Erlangen-Nürnberg Medical School. Recruitment status was: Recruiting First Posted : February 19, 2010 Last Update Posted : January 24, 2013 (...) Sponsor: University of Erlangen-Nürnberg Medical School Information provided by (Responsible Party): Helmut Neumann, University of Erlangen-Nürnberg Medical School Study Details Study Description Go to Brief Summary: The main objective of this study is to determine the frequency of different gastrointestinal disorders as the cause of diarrhea in patients at a tertiary referral center using confocal laser endomicroscopy. Condition or disease Intervention/treatment Diarrhea Procedure: Colonoscopy

2010 Clinical Trials

199. Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome

) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion criteria: Diarrhea or diarrhea predominant IBS patients Age 18 to 65 BDQ confirms presence of IBS-D or functional diarrhea, positive by Rome III criteria No restrictions on Hospital Anxiety Depression score No abdominal surgery (except appendectomy and cholecystectomy) Exclusion criteria: Serum tissue transglutaminase IgA or IgG positive or medical record of small bowel biopsy suggestive of celiac disease Use of tobacco (...) Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2010 Clinical Trials

200. Safety and Efficacy Study of a Vaccine Against Enterotoxigenic Escherichia Coli (ETEC) to Prevent Moderate to Severe Diarrhea

on an outpatient basis. Biological: Placebo Placebo Outcome Measures Go to Primary Outcome Measures : Severe diarrhea: ≥6 grade 3-5 stools in 24 hrs, or >800g of grade 3-5 stools in 24 hrs and moderate diarrhea: 4-5 grade 3-5 stools in 24 hrs or 401-800g of grade 3-5 stools in 24 hrs [ Time Frame: Study Day 49 to 57 ] Secondary Outcome Measures : Number of subjects with severe diarrhea (if any) [ Time Frame: Study Day 49 to 57 ] Number of subjects with diarrhea of any severity [ Time Frame: Study Day 49 to 57 (...) or more than 3 per day). Regular use of laxatives, antacids, or other agents to lower stomach acidity. Use of any medication known to affect the immune function (e.g., corticosteroids and others) within 30 days preceding the first vaccination or planned use during the active study period. Known allergy to two of the following antibiotics: quinolones, trimethoprim-sulfamethoxazole, and penicillin. Symptoms consistent with Traveler's Diarrhea concurrent with travel to countries where ETEC infection

2010 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>